Top-News
Gesundheitswesen Schweden

Vivesto AB News

Aktie
WKN:  509722 ISIN:  SE0000722365
0,0225 €
+0,0001 €
+0,45%
03.05.24 09:15:30
Handeln Depot/Watchlist
Aktienanzahl *
538,04 Mio.
Marktkapitalisierung *
11,73 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 05.04.2024

Vivesto AB News

08.10.21 - DGAP
Oasmia Pharmaceutical (OASM): Focused on pillars of growth
Edison Investment Research Limited Oasmia Pharmaceutical (OASM): Focused on pillars of growth 08-Oct-2021 / 10:18 GMT/BST London, UK, 8 October 2021 Oasmia ...
09.09.20 - DGAP
Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM)
Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM) 09-Sep-2020 / 14:59 GMT/BST London, ...
09.01.20 - GlobeNewswire
Oasmia to present at Biotech Showcase in San Francisco
Oasmia Pharmaceutical AB has been selected to present at the Biotech Showcase Conference and will be presenting its technology on Tuesday 14 January at 15:30 (3:30 pm), ...
30.12.19 - GlobeNewswire
New number of shares and votes in Oasmia Pharmaceutical AB (publ)
The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the preferential rights issue completed in December 2019. As a result of the ...
30.12.19 - GlobeNewswire
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019
EVENTS IN SECOND QUARTER Oasmia ADSs were delisted from NASDAQ in the US to reduce complexity and costs. Oasmia recruited two General Managers to its management ...
09.12.19 - GlobeNewswire
Final result of the rights issue in Oasmia
06.12.19 - GlobeNewswire
Oasmia’s rights issue has been oversubscribed
27.11.19 - GlobeNewswire
Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue
In a previous press release today, November 27, it was stated that Oasmia Pharmaceutical AB's CEO Sven Rohmann bought 978,944 subscription rights in the company. The ...
27.11.19 - GlobeNewswire
The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue
Oasmia Pharmaceutical AB ("Oasmia" or "the Company") CEO Sven Rohmann and the Chairman of the Board Jörgen Olsson today announced that they have purchased 978,944 ...
19.11.19 - GlobeNewswire
Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States ...
18.11.19 - GlobeNewswire
Oasmia invites to investor meetings in connection to the rights issue
The Board of Directors of Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) invites to investor meetings in connection to the subscription period of the rights issue which ...
11.11.19 - GlobeNewswire
Oasmia resolves on a rights issue of approximately SEK 399 million
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States ...
06.11.19 - GlobeNewswire
Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019
14.10.19 - GlobeNewswire
Notice of extraordinary general meeting in Oasmia Pharmaceutical AB
The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the ...
14.10.19 - GlobeNewswire
The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million
The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the ...
26.09.19 - GlobeNewswire
Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019
This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail.
26.09.19 - GlobeNewswire
Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019
EVENTS IN FIRST QUARTER
18.09.19 - GlobeNewswire
Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte
In connection with Oasmia's year-end report in June 2019, the company's Board of Directors made a decision to engage a special examiner, audit firm Deloitte (Svante Forsberg ...
18.09.19 - GlobeNewswire
Oasmia presents Q1 report through audiocast on September 26
Oasmia will hold an audiocast and telephone conference on Thursday 26 September at 10:00 (CET) to present the company's Q1 report for the financial year 2019/2020.
15.09.19 - GlobeNewswire
The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019
Oasmia's Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019.

Newssuche

Videos

newspaper
03.05.24 -13,45%
Technical Trading: Gold freitags Long
Gold Long Typ: Turbo Open End WKN: NG8DB8 Hebel: 27 Laufzeit: OpenEnd Einstieg: Market ... Mehr »